BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed C ...
manilatimes4d
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...
Cell polarity coordinates jellyfish larval development along a central axis, study finds
Scientists have uncovered a key mechanism in jellyfish embryos that provides new insights into how the body plan of these ...
Pacylex Pharmaceuticals Presents Progress on NMT Inhibitors for Cancer at February Industry Conferences
Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...